• Consensus Rating: Hold
  • Consensus Price Target: $249.40
  • Forecasted Upside: 14.15%
  • Number of Analysts: 16
  • Breakdown:
  • 2 Sell Ratings
  • 6 Hold Ratings
  • 8 Buy Ratings
  • 0 Strong Buy Ratings
$218.48
▲ +1.53 (0.71%)

This chart shows the closing price for ILMN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Illumina Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ILMN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ILMN

Analyst Price Target is $249.40
▲ +14.15% Upside Potential
This price target is based on 16 analysts offering 12 month price targets for Illumina in the last 3 months. The average price target is $249.40, with a high forecast of $350.00 and a low forecast of $150.00. The average price target represents a 14.15% upside from the last price of $218.48.

This chart shows the closing price for ILMN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 16 polled investment analysts is to hold stock in Illumina. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 3 hold ratings
  • 2 sell ratings
9/29/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 2 sell ratings
12/28/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 4 hold ratings
  • 3 sell ratings
3/28/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 3 hold ratings
  • 2 sell ratings
6/26/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 5 hold ratings
  • 2 sell ratings
9/24/2022
  • 0 strong buy ratings
  • 7 buy ratings
  • 4 hold ratings
  • 2 sell ratings
12/23/2022
  • 0 strong buy ratings
  • 8 buy ratings
  • 6 hold ratings
  • 2 sell ratings
2/21/2023
  • 0 strong buy ratings
  • 8 buy ratings
  • 6 hold ratings
  • 2 sell ratings
3/23/2023

Latest Recommendations

  • 0 strong buy ratings
  • 8 buy ratings
  • 6 hold ratings
  • 2 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/15/2023Royal Bank of CanadaLower TargetOutperform$303.00 ➝ $300.00Low
2/14/2023UBS GroupLower TargetNeutral$255.00 ➝ $240.00Low
2/8/2023Piper SandlerReiterated RatingOverweight$290.00Low
2/8/2023Stifel NicolausLower Target$285.00 ➝ $235.00Low
2/8/2023JPMorgan Chase & Co.Lower TargetNeutral$300.00 ➝ $271.00Low
2/8/2023Royal Bank of CanadaBoost TargetOutperform$284.00 ➝ $303.00Low
2/8/2023Bank of AmericaBoost Target$210.00 ➝ $230.00Low
2/8/2023SVB LeerinkBoost TargetOutperform$249.00 ➝ $250.00Low
2/8/2023BarclaysLower TargetUnderweight$160.00 ➝ $150.00Low
1/27/2023Piper SandlerLower Target$300.00 ➝ $290.00Low
1/25/2023ArgusDowngradeBuy ➝ HoldLow
1/17/2023Canaccord Genuity GroupLower TargetBuy$330.00 ➝ $300.00Low
1/10/2023Bank of AmericaLower Target$220.00 ➝ $210.00Low
1/10/2023CowenLower Target$350.00 ➝ $296.00Low
1/4/2023ScotiabankInitiated CoverageSector Perform$216.00Low
12/20/2022OTR GlobalUpgradeMixed ➝ PositiveLow
12/12/2022CitigroupDowngradeNeutral ➝ Sell$200.00 ➝ $180.00Low
12/6/2022Royal Bank of CanadaInitiated CoverageOutperform$282.00Low
11/14/2022Piper SandlerLower TargetOverweight$320.00 ➝ $300.00Low
11/7/2022Morgan StanleyLower TargetEqual Weight$240.00 ➝ $225.00Low
11/4/2022Canaccord Genuity GroupLower TargetBuy ➝ Buy$340.00 ➝ $330.00Low
11/4/2022CowenBoost Target$327.00 ➝ $350.00Low
11/4/2022Credit Suisse GroupLower TargetNeutral$230.00 ➝ $225.00N/A
11/4/2022CowenBoost Target$327.00 ➝ $350.00Low
11/4/2022Robert W. BairdLower Target$215.00 ➝ $210.00Low
10/11/2022ArgusLower Target$300.00 ➝ $250.00Low
10/4/2022SVB LeerinkUpgradeMarket Perform ➝ Outperform$220.00 ➝ $270.00Low
9/30/2022BarclaysBoost TargetUnderweight$130.00 ➝ $175.00Low
9/28/2022OTR GlobalDowngradePositiveLow
9/28/2022Evercore ISIUpgradeIn-Line ➝ Outperform$170.00 ➝ $250.00Low
8/24/2022Credit Suisse GroupInitiated CoverageNeutral$230.00Low
8/17/2022UBS GroupLower TargetNeutral$350.00 ➝ $245.00Low
8/15/2022Evercore ISILower Target$170.00N/A
8/15/2022CowenLower Target$327.00N/A
8/15/2022BarclaysLower Target$130.00N/A
8/15/2022Atlantic SecuritiesLower Target$190.00N/A
8/12/2022Morgan StanleyLower TargetEqual Weight$350.00 ➝ $240.00Low
8/12/2022Bank of AmericaLower Target$220.00 ➝ $200.00Low
8/12/2022Piper SandlerLower TargetOverweight$360.00 ➝ $320.00Low
8/12/2022Canaccord Genuity GroupLower TargetBuy ➝ Buy$450.00 ➝ $380.00Low
8/12/2022SVB LeerinkLower TargetMarket Perform$225.00 ➝ $220.00Low
8/12/2022Stifel NicolausLower TargetBuy$480.00 ➝ $300.00Low
8/12/2022CitigroupLower TargetNeutral$220.00 ➝ $200.00Low
8/12/2022Robert W. BairdLower Target$306.00 ➝ $215.00Low
7/19/2022CowenSet Target$412.00Low
7/13/2022BarclaysDowngradeEqual Weight ➝ Underweight$350.00 ➝ $150.00N/A
7/8/2022CitigroupLower TargetNeutral$325.00 ➝ $220.00N/A
5/15/2022Piper SandlerLower TargetNA$460.00 ➝ $360.00Low
5/6/2022Canaccord Genuity GroupLower TargetBuy ➝ Buy$555.00 ➝ $520.00High
5/6/2022CowenLower Target$506.00 ➝ $492.00High
5/6/2022CowenLower Target$506.00 ➝ $492.00High
5/6/2022CitigroupLower Target$400.00 ➝ $325.00High
3/29/2022OTR GlobalUpgradeMixed ➝ PositiveMedium
2/15/2022Piper SandlerBoost TargetOverweight$450.00 ➝ $460.00Medium
2/11/2022Robert W. BairdLower Target$437.00 ➝ $380.00High
2/11/2022SVB LeerinkLower TargetMarket Perform$430.00 ➝ $400.00High
1/18/2022Stifel NicolausUpgradeHold ➝ Buy$480.00High
1/11/2022BarclaysUpgradeUnderweight ➝ Equal Weight$432.72 ➝ $412.00High
1/11/2022SVB LeerinkBoost TargetMarket Perform$420.00 ➝ $430.00High
1/10/2022BarclaysLower TargetUnderweight$365.00 ➝ $350.00High
1/7/2022Bank of AmericaUpgradeUnderperform ➝ Neutral$390.00High
1/6/2022CitigroupLower TargetNeutral ➝ Neutral$450.00 ➝ $400.00High
1/6/2022Morgan StanleyInitiated CoverageNeutral ➝ Equal Weight$425.00High
11/8/2021Robert W. BairdLower TargetNeutral$493.00 ➝ $437.00High
10/19/2021SVB LeerinkLower TargetMarket Perform$425.00 ➝ $420.00Low
8/22/2021Robert W. BairdReiterated RatingHoldMedium
8/19/2021SVB LeerinkDowngradeOutperform ➝ Market Perform$425.00High
8/6/2021BarclaysBoost TargetUnderweight$355.00 ➝ $365.00Low
8/6/2021Piper SandlerBoost TargetOverweight$510.00 ➝ $560.00High
7/29/2021SVB LeerinkReiterated RatingBuyLow
7/13/2021BarclaysBoost TargetUnderweight$300.00 ➝ $355.00Low
4/28/2021Wells Fargo & CompanyBoost TargetUnderweight$330.00 ➝ $340.00High
4/6/2021Wells Fargo & CompanyBoost TargetUnderweight$300.00 ➝ $330.00Medium
3/31/2021Atlantic SecuritiesDowngradeOverweight ➝ Neutral$390.00High
3/2/2021BarclaysInitiated CoverageUnderweight$325.00High
2/16/2021BTIG ResearchBoost TargetBuy$410.00 ➝ $570.00Low
2/12/2021Piper SandlerBoost TargetOverweight$415.00 ➝ $510.00Low
2/12/2021CowenBoost TargetOutperform$385.00 ➝ $460.00Low
2/12/2021SVB LeerinkBoost TargetOutperform$360.00 ➝ $470.00Low
12/22/2020OTR GlobalUpgradePositiveMedium
12/22/2020Piper SandlerUpgradeNeutral ➝ Overweight$340.00 ➝ $415.00Medium
12/17/2020BTIG ResearchUpgradeNeutral ➝ Buy$410.00Medium
12/16/2020Smith Barney CitigroupBoost Target$330.00 ➝ $335.00Low
12/7/2020SVB LeerinkBoost TargetPositive ➝ Outperform$325.00 ➝ $360.00Low
12/1/2020ArgusLower Target$380.00 ➝ $355.00Low
10/30/2020SVB LeerinkBoost TargetOutperform$315.00 ➝ $325.00High
10/13/2020GuggenheimDowngradeBuy ➝ NeutralMedium
9/30/2020Atlantic SecuritiesInitiated CoverageOverweight$355.00 ➝ $355.00Medium
9/29/2020Wolfe ResearchDowngradeOutperform ➝ Peer PerformLow
9/22/2020Robert W. BairdLower TargetNeutral$335.00 ➝ $281.00Low
9/22/2020SVB LeerinkLower TargetOutperform$360.00 ➝ $315.00Low
9/22/2020Stifel NicolausDowngradeBuy ➝ Hold$380.00 ➝ $280.00Low
9/22/2020UBS GroupDowngradeBuy ➝ Neutral$390.00 ➝ $285.00Low
9/21/2020JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$390.00 ➝ $280.00Low
9/21/2020GuggenheimUpgradeNeutral ➝ Buy$345.00High
9/11/2020ArgusReiterated RatingBuy ➝ Reduce$380.00 ➝ $380.00Low
9/9/2020Morgan StanleyInitiated CoverageEqual Weight$400.00Low
8/7/2020SVB LeerinkLower TargetOutperform$370.00 ➝ $360.00High
8/7/2020Evercore ISIDowngradeIn-Line ➝ Underperform$310.00High
8/7/2020Piper SandlerDowngradeOverweight ➝ Neutral$356.00 ➝ $340.00High
7/7/2020GuggenheimDowngradeBuy ➝ NeutralLow
7/2/2020JPMorgan Chase & Co.Boost TargetOverweight$340.00 ➝ $390.00Low
5/21/2020ArgusBoost Target$340.00 ➝ $380.00Low
5/1/2020Piper SandlerLower TargetPositive ➝ Overweight$370.00 ➝ $356.00Low
5/1/2020Wells Fargo & CompanyBoost TargetUnderweight$245.00 ➝ $290.00Low
5/1/2020Stifel NicolausBoost TargetBuy$298.00 ➝ $325.00High
5/1/2020CowenBoost TargetOutperform$275.00 ➝ $320.00Medium
4/24/2020CitigroupDowngradeBuy ➝ Neutral$250.00 ➝ $320.00Low
4/21/2020Robert W. BairdDowngradeOutperform ➝ Neutral$310.00High
4/15/2020Robert W. BairdLower TargetOutperform ➝ Outperform$339.00 ➝ $310.00Medium
4/2/2020Stifel NicolausLower TargetBuy$345.00 ➝ $298.00Medium
3/30/2020Wells Fargo & CompanyLower TargetUnderweight$290.00 ➝ $245.00Medium
3/26/2020BarclaysLower TargetOverweight$390.00 ➝ $350.00High
3/20/2020CitigroupLower TargetBuy$350.00 ➝ $250.00Low
2/4/2020Credit Suisse GroupReiterated RatingBuy$340.00Low
1/30/2020Wells Fargo & CompanyLower TargetUnderweight$300.00 ➝ $290.00Low
1/30/2020CitigroupLower TargetBuy$385.00 ➝ $350.00High
1/9/2020Piper SandlerBoost TargetOverweight$341.00 ➝ $370.00Low
1/7/2020Wells Fargo & CompanyInitiated CoverageUnderweight$300.00Medium
1/6/2020CitigroupInitiated CoverageBuy$385.00Low
1/3/2020UBS GroupUpgradeNeutral ➝ Buy$355.00Medium
12/18/2019CowenReiterated RatingOutperform$320.00 ➝ $335.00Medium
11/14/2019Stifel NicolausInitiated CoverageBuy$345.00Medium
10/25/2019CowenSet TargetBuy$320.00Low
10/25/2019Wolfe ResearchSet TargetBuy$380.00N/A
10/25/2019Piper Jaffray CompaniesLower TargetOverweight$348.00 ➝ $341.00High
10/25/2019GuggenheimInitiated CoverageBuy ➝ Buy$350.00 ➝ $350.00High
9/27/2019Piper Jaffray CompaniesSet TargetBuy$348.00Medium
9/25/2019ArgusBoost TargetBuy$300.00 ➝ $340.00Medium
7/31/2019Credit Suisse GroupReiterated RatingBuy$340.00Medium
7/30/2019UBS GroupBoost TargetBuy$350.00 ➝ $355.00Low
7/30/2019Piper Jaffray CompaniesLower TargetOverweight$382.00 ➝ $348.00Low
7/18/2019ArgusLower TargetBuy$340.00Low
7/12/2019CowenLower TargetOutperform$380.00 ➝ $320.00Low
7/12/2019Deutsche Bank AktiengesellschaftLower TargetHold$290.00 ➝ $280.00High
7/12/2019Bank of AmericaDowngradeBuy ➝ Underperform$310.00High
5/30/2019Wolfe ResearchInitiated CoverageOutperform ➝ OutperformLow
4/2/2019OTR GlobalDowngradePositiveLow
1/30/2019Bank of AmericaReiterated RatingBuy$355.00Low
1/30/2019SVB LeerinkUpgradeOutperform$380.00 ➝ $365.00High
1/25/2019Deutsche Bank AktiengesellschaftDowngradeBuy ➝ Hold$296.53Medium
1/7/2019Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$320.00 ➝ $288.00Medium
1/3/2019UBS GroupUpgradeNeutral ➝ Buy$340.00 ➝ $370.00High
10/24/2018BarclaysBoost TargetOverweight ➝ Overweight$350.00 ➝ $370.00High
10/12/2018Deutsche Bank AktiengesellschaftBoost TargetBuy$350.00Low
10/9/2018UBS GroupInitiated CoverageNeutral ➝ Neutral$340.00Low
10/2/2018Piper Jaffray CompaniesBoost TargetOverweight$380.00Medium
9/6/2018CowenBoost TargetOutperform ➝ Positive$315.00 ➝ $400.00Low
8/10/2018ArgusSet TargetBuy ➝ Buy$310.00 ➝ $372.00Medium
8/7/2018Morgan StanleyUpgradeUnderweight ➝ Equal Weight$210.00 ➝ $320.00Low
7/31/2018JPMorgan Chase & Co.Boost TargetOverweight$350.00Medium
7/31/2018Bank of AmericaBoost TargetBuy ➝ Buy$345.00 ➝ $370.00High
7/31/2018Deutsche Bank AktiengesellschaftBoost TargetBuy ➝ Buy$280.00 ➝ $330.00High
7/31/2018CitigroupBoost TargetBuy ➝ Buy$330.00 ➝ $345.00High
7/31/2018BarclaysBoost TargetOverweight ➝ Overweight$300.00 ➝ $350.00High
7/31/2018Piper Jaffray CompaniesReiterated RatingPositive ➝ Overweight$350.00High
7/17/2018Piper Jaffray CompaniesBoost TargetOverweight ➝ Overweight$272.00 ➝ $329.00Low
7/13/2018Morgan StanleyBoost TargetUnderweight$195.00 ➝ $210.00Medium
7/10/2018CowenBoost TargetOutperform ➝ Outperform$275.00 ➝ $315.00High
6/25/2018CitigroupBoost TargetBuy ➝ Buy$275.00 ➝ $330.00High
5/31/2018Morgan StanleyBoost TargetUnderweight ➝ Underweight$180.00 ➝ $195.00Low
5/7/2018BarclaysUpgradeEqual Weight ➝ Overweight$235.00High
4/25/2018BarclaysBoost TargetEqual Weight ➝ Equal Weight$215.00 ➝ $235.00Medium
4/25/2018Morgan StanleyBoost TargetUnderweight ➝ Underweight$170.00 ➝ $180.00Medium
4/25/2018BTIG ResearchReiterated RatingHoldHigh
4/25/2018Robert W. BairdBoost TargetOutperform ➝ Outperform$261.00 ➝ $271.00High
4/11/2018Morgan StanleyBoost TargetUnderweight ➝ Underweight$157.00 ➝ $170.00Low
(Data available from 3/24/2018 forward)

News Sentiment Rating

0.10 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 10 very positive mentions
  • 37 positive mentions
  • 9 negative mentions
  • 3 very negative mentions
8/26/2022
  • 6 very positive mentions
  • 33 positive mentions
  • 8 negative mentions
  • 5 very negative mentions
9/25/2022
  • 7 very positive mentions
  • 30 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
10/25/2022
  • 12 very positive mentions
  • 30 positive mentions
  • 7 negative mentions
  • 2 very negative mentions
11/24/2022
  • 5 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 8 very negative mentions
12/24/2022
  • 10 very positive mentions
  • 13 positive mentions
  • 9 negative mentions
  • 2 very negative mentions
1/23/2023
  • 17 very positive mentions
  • 28 positive mentions
  • 4 negative mentions
  • 3 very negative mentions
2/22/2023
  • 16 very positive mentions
  • 21 positive mentions
  • 7 negative mentions
  • 9 very negative mentions
3/24/2023

Current Sentiment

  • 16 very positive mentions
  • 21 positive mentions
  • 7 negative mentions
  • 9 very negative mentions

Recent Stories by Sentiment

Illumina logo
Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through the Core Illumina segment, which serves customers in the research, clinical and applied markets fields, and enables the adoption of a variety of genomic solutions. The firm's products include instruments, kits and reagents, selection tools, and software and analysis. Its services include sequencing and microarray services, proactive instrument monitoring, and instrument services, training, and consulting. The company was founded by David R. Walt, John R. Stuelpnagel, Anthony W. Czarnik, Lawrence A. Bock, and Mark S. Chee in April 1998 and is headquartered in San Diego, CA.
Read More

Today's Range

Now: $218.48
Low: $214.24
High: $219.22

50 Day Range

MA: $210.38
Low: $194.01
High: $228.15

52 Week Range

Now: $218.48
Low: $173.45
High: $371.16

Volume

129,535 shs

Average Volume

1,358,953 shs

Market Capitalization

$34.52 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.15

Frequently Asked Questions

What sell-side analysts currently cover shares of Illumina?

The following Wall Street sell-side analysts have issued research reports on Illumina in the last year: Argus, Atlantic Securities, Bank of America Co., Barclays PLC, Canaccord Genuity Group Inc., Citigroup Inc., Cowen Inc, Cowen Inc., Credit Suisse Group AG, Evercore ISI, JPMorgan Chase & Co., Morgan Stanley, OTR Global, Piper Sandler, Robert W. Baird, Royal Bank of Canada, Scotiabank, Stifel Nicolaus, StockNews.com, SVB Leerink LLC, TheStreet, and UBS Group AG.
View the latest analyst ratings for ILMN.

What is the current price target for Illumina?

20 Wall Street analysts have set twelve-month price targets for Illumina in the last year. Their average twelve-month price target is $249.40, suggesting a possible upside of 15.0%. Cowen Inc. has the highest price target set, predicting ILMN will reach $350.00 in the next twelve months. Barclays PLC has the lowest price target set, forecasting a price of $150.00 for Illumina in the next year.
View the latest price targets for ILMN.

What is the current consensus analyst rating for Illumina?

Illumina currently has 2 sell ratings, 6 hold ratings and 8 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in ILMN, but not buy more shares or sell existing shares.
View the latest ratings for ILMN.

What other companies compete with Illumina?

How do I contact Illumina's investor relations team?

Illumina's physical mailing address is 200 ILLUMINA WAY, SAN DIEGO CA, 92122. The life sciences company's listed phone number is (858) 202-4500 and its investor relations email address is [email protected] The official website for Illumina is www.illumina.com. Learn More about contacing Illumina investor relations.